(Journal Article): Polyclonal Anti-T-Cell Therapy for Type 1 Diabetes Mellitus of Recent Onset
 
Saudek F, Havrdova T, Boucek P, Karasova L, Novota P, Skibova J (Diabetes Center, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21 Prague 4, Czech Republic, frantisek.saudek@medicon.cz )
 
IN: Rev Diabetic Stud 2004; 2(1):80-88
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: The destruction of pancreatic beta-cells in type 1 diabetes mellitus is mediated by autoreactive T-lymphocyte clones. We initiated a prospective randomized controlled trial of polyclonal rabbit anti-T-cell globulin (ATG) in patients with type 1 diabetes within 4 weeks of diagnosis and with residual post-glucagon C-peptide levels still over 0.3 nmol/l. ATG was administered as an initial bolus of 9 mg/kg followed by 3 consecutive doses of 3 mg/kg. An interim analysis was performed to establish whether any significant changes in C-peptide production and insulin requirement had occurred that would justify the continuation of this pilot study. By May 2004, 11 subjects were assigned to treatment with ATG along with intensified insulin therapy and 6 to intensified insulin therapy with placebo, and were followed for a period of at least 6 months. During the first 12 months a significant difference in the insulin dose trends was found between the groups (p=0.010) with a lower insulin dosage in the ATG group. There was also a difference in the glucagon stimulated C-peptide level trends of marginal significance (p=0.068). Compared to values at screening, stimulated C-peptide levels significantly improved in the ATG group (p=0.012) but not in the placebo group. Complete diabetes remission occurred in 2 patients in the ATG and in none of the placebo group. Glycosylated hemoglobin at 12 months tended to be lower in the ATG group (p=0.088). Significant adverse effects of ATG treatment, mainly transient fever and moderate symptoms of serum sickness (7 and 6 subjects, respectively) were observed during the first month only. The interim analysis of this ongoing study suggests that short-term ATG therapy in type 1 diabetes of recent onset contributes to the preservation of residual C-peptide production and to lower insulin requirements in the first year following diagnosis.

TYPE OF PUBLICATION: Original article

REFERENCES:

1. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ 2004. 328:750-754.
2. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001. 358:221-229.
3. Roep BO. The role of T cells in the pathogenesis of type 1 diabetes: From cause to cure. Diabetologia 2003. 46(3):305-321.
4. Winter WE, Schatz D. Prevention strategies for type 1 diabetes mellitus. Biodrugs 2003. 17:39-64.
5. Nerup J. Rationale of immune intervention of type 1 diabetes. In: Andreani D, Kolb H, Pozzili P. Immunotherapy of type 1 diabetes. John Willey and Sons 1989. pp 5-11.
6. Chatenoud L. Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity: its relevance for treatment in established diabetes and islet transplantation. Diabetologia 2001. 44:521-536.
7. Skyler JS, Lorenz TJ, Schwatz S, Eisenbarth GS, Einhorn D, Palmer JP, Marks JB, Greenbaum C, Saria EA, Byers V. Effects of an anti-CD5 immunoconjugate (CD5-Plus) in recent onset type 1 diabetes mellitus: a preliminary investigation. J Diab Comp 1993. 7:224-232.
8. Vialetts B, Vague P. Treatment of diabetes by monoclonal antibodies. Lessons from a pilot study using anti-IL-2 receptor MoAb in recently diagnosed diabetic patients. Diabetes Prev Ther 1991. 5:21-22.
9. Boitard C, Timsit J, Assan R, Mogenet A, Debussche X, Kaloustlan E, Attali JR, Chanson P, Chatenoud L, Woodworth T, et al. Treatment of type 1 diabetes mellitus with DAB486-IL2, a toxin conjugate witch targets activated T-lymphocytes. Diabetologia 1992. 35(suppl 1):A218. [DOD]
10. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman S, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002. 346:1692-1698.
11. Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003. 75:657-662.
12. Pistillo MP, Tazzari PL, Bonifazi F, Bandini G, Kato T, Matsui T, Nishioka K, Conte R, Ferrara GB. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients. Transplantation 2002. 73:1295-1302.
13. Schatz DA, Riley WJ, Silverstein JH, Barett DJ. Long-term immunoregulatory effects of therapy with corticosteroids and anti-thymocyte globulin. Immunoparm Im¬munotoxicol 1989. 11:269-287.
14. Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T, Morris MA. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diab Res 1985. 2:271-276.
15. Maes BD, Vanrenterghem YF. Induction with polyclonal antibodies. Curr Opin Organ Transplant 1999. 4:305-311.
16. Saudek F, Adamec M, Koznarova R, Boucek P, Voska L. Low rejection rate with high-dose ATG bolus therapy in simultaneous pancreas and kidney transplantation. Transplant Proc 2001. 33:2304-2306.
17. Stratton RJ, Wolson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology 2001. 40:84-88.
18. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis. A randomized pilot study. Neurology 2003. 61:260-262.
19. Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, Miedema K, Mosca A, Mauri P, Paroni R, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002. 40:78-89.
20. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993. 41:119-134.
21. Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, Bach JF. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids. Transplantaton 1990. 49:697-702.
22. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone J. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest 2003. 111:409-418.
23. Leimenstoll G, Zerrenthin N, Niedermayer W, Steinmann J. An antilymphocyte globulin of rabbit origin inhibits the antigen induced activation of alloreactive T cells by blocking CD2. Transplant Proc 1991. 23:982-984.
24. Bonnefoy-Berard N, Revillard JP. Mechanism of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996. 15:435-442.
25. Starzl ET, Murase N, Abu-Elmagd K, Gray EA, Shapiro R, Eghtesad B, Corry RJ, Jordan ML, Fontes P, Gayowski T, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003. 361:1502-1510.
26. Shapiro R, Jordan ML, Basu A, Scantlebury V, Potdar S, Tan HP, Gray EA, Randhawa PS, Murase N, Zeevi A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003. 238:520-525.
27. Diabetes Control and Complications Trial Research Study Group. Effects of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: a randomized, controlled trial. Ann Intern Med 1998. 128:517-523.
28. Greenbaum CJ, Harrison LC. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003. 52:1059-1065.